The global market for hyperphosphatemia treatment is expected to be valued at around US$ 12.66 Billion in 2023 and is projected to expand at a CAGR of over 4.8% through 2033. The market is expected to surpass a staggering value of US$ 20.24 Billion by 2033.
In chronic kidney disease, hyperphosphatemia affects 70% of people. In a unanimous vote (9 to 4) for the use of Tenapanor (Xphozah®) as monotherapy in adult patients who are undergoing dialysis for controlling serum phosphorus, as well as in combination with phosphate binders (10 to 2, with one abstention), the Food and Drug Administration (FDA) Cardiovascular and Renal Drugs Advisory Committee approved Tenapanor (Xphozah®) monotherapy.
The condition of hyperphosphatemia can have a significant impact on soft tissue and cardiovascular calcification. In order to improve patient’s quality of life and longevity, the National Kidney Foundation's Kidney Disease Outcome Quality Initiative (K/DOQI) Clinical Practice Guidelines for Bone Metabolism and Disease in Chronic Kidney Disease recommend stricter levels of serum phosphorus and calcium-phosphate product control.
Research in recent years has greatly contributed to improving the understanding of ESRD patients with hyperphosphatemia's pathophysiology. Patients on hemodialysis who have hyperphosphatemia may experience a significant reduction in mortality rates associated with cardiac disease if they receive appropriate and continuous education about the use of their medications.
| Data Points | Key Statistics |
|---|---|
| Anticipated Base Year Value (2022) | US$ 10.1 Billion |
| Expected Market Value (2023) | US$ 12.66 Billion |
| Projected Forecast Value (2033) | US$ 20.24 Billion |
| Global Growth Rate (2023 to 2033) | 4.8% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to Fact.MR, hyperphosphatemia sales grew at a CAGR of 4% in the historical period 2018 to 2022. During the forecast period, the demand for emerging therapies will also be fueled by the expected launch of novel treatments and pharmaceutical companies' research and development activities. Proactively pursuing reimbursement during late development and after launch can have a beneficial effect.
Phosphate-binder treatment has made recent advances. As a result of hypercalcemia, sevelamer, and lanthanum are effective in the prevention of cardiovascular mortality. Some patients may benefit from the newly approved iron-based products, but there's no data on long-term safety. For pharmacists to optimize hyperphosphatemia therapy, knowing these new treatments is crucial as essential members of the care team.
Globally, chronic kidney diseases are becoming more prevalent, resulting in significant growth in new drug development and therapeutics. In recent years, new therapies have been conceptualized based on new mechanistic understandings of phosphorus absorption. Accordingly, the market for hyperphosphatemia treatment is projected to grow at a CAGR of 4.8% between 2023 and 2033.
A Growing Number of Health Conditions will drive Hyperphosphatemia Market Demand
The growing prevalence of chronic diseases and the growing geriatric population are expected to drive the market demand for hyperphosphatemia treatments. As Chronic Kidney Disease (CKD) and End-Stage Renal Disease (ESRD) patients become more prevalent, the market will witness a surge in investment and development of newer mechanisms of action.
As the FDA and other government funding bodies continue to grow in the coming years, it is expected that the market will continue to grow. With the increase in Research and Development funding and the development of biotechnology advancements and studies, the market for hyperphosphatemia is expected to grow in the upcoming years. The market for hyperphosphatemia diagnosis and drug treatments is expected to grow further due to the growing number of anemic women in emerging countries and anemic conditions in children.
Insights into the Future of Hyperphosphatemia Markets
Researchers have investigated a number of hyperphosphatemia treatment approaches to reduce its burden. Various treatments for hyperphosphatemia that lower phosphate levels have been demonstrated to be successful in controlling and preventing hyperphosphatemia through the use of these strategies.
With the launch of more drugs in developing economies, the hyperphosphatemia treatment market is expected to witness significant growth in the near future. For instance, Vifor Fresenius Medical Care Renal Pharma (VFMCRP) revealed that Velphoro (PA21) lowered serum phosphorus in CKD dialysis patients in April 2021.
Furthermore, studies also showed using Raman spectroscopy and attenuated total reflectance Fourier transform infrared spectroscopy, the researchers confirmed the formation of noncovalent hydrogen bonds in the hetero synthon. For instance, Sanofi-Aventis Korea announced in March that it had entered into a joint marketing and sales agreement with Handok for the latter's hyperphosphatemia treatment Renvela.
Principal Consultant
Phosphate levels that are too high can cause serious health conditions if left untreated. Among them are diabetes and kidney disease. A treatment program may be needed to prevent this condition from developing. The market for hyperphosphatemia is expected to grow at a brisk pace, but there are a few factors that may hinder its growth, including a poor understanding of what phosphate levels are in food products and the lack of data on how phosphates are managed, a significant cost, and increased competition within the industry make it difficult to manage them.
Moreover, the stricter regulations imposed by the regulatory agencies will further impede the sales of hyperphosphatemia drugs, which will further dampen the demand for these drugs. A rise in side effects associated with drugs and the high cost of diagnosis is expected to hamper the growth of this industry.
New Entrants Lead to Improvement in Hyperphosphatemia
With technological advancements in the hyperphosphatemia field, new companies are entering the market and gaining a competitive edge. In order to stay ahead of changing consumer preferences, these companies continually invest in research and development. By advancing the market, the company aims to improve its position in the hyperphosphatemia market.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Increased Advances in Drugs, along with Investments to propel Market Expansion
According to the forecast, North American sales will account for 36% of the overall demand in the forthcoming decade. In North America, hyperphosphatemia diagnosis investments are rising, which will lead to market dominance. Health awareness and the availability of modern diagnostic facilities have made the United States the dominant market in North America.
North America is by far the global market leader in terms of medications for hyperphosphatemia, both in terms of income and in terms of the number of patients. Among the North American population, hyperphosphatemia therapeutics are growing at an accelerating rate as diabetes, osteoporosis, and a variety of chronic renal diseases are on the rise. Chronic kidney disease (CKD) affects about 15% of American adults, and 1 in 3 are at risk. There are approximately 560,000 dialysis patients in the United States. The burden of chronic kidney disease and end-stage renal disease is disproportionately higher for minorities; the likelihood that Black Americans require dialysis is 4 times higher than that of White Americans.
Moreover, the rising prevalence of hyperphosphatemia as well as the development of osteoporosis and a variety of chronic kidney diseases are driving the growth of the market for hyperphosphatemia therapeutic drugs in North America. A recent study by Block et al concluded that despite attempts made by patients, dietitians, and nephrologists to reach 5.5 mg/dL as the recommended goal for serum phosphorus, approximately 60% of American patients on hemodialysis have phosphorus levels above this goal.
Pharmaceuticals will Dominate the Emerging Markets Hyperphosphatemia Market
Estimates indicate that Asia Pacific will dominate the global market. Globally, this region generates 32% of the revenues generated worldwide, making up a substantial portion of global revenues. Asia-Pacific is experiencing the fastest market growth. In the Asia-Pacific region, China is expected to be the biggest market, both in revenue and size. With China's central government's robust growth initiatives, it is expected that the country's healthcare infrastructure will increase the demand for hyperphosphatemia medications.
As the FDA approves more of these drugs, and dialysis services increase in major countries, phosphate binders in the region are in greater demand. Emerging countries, such as China, India, and Brazil, are distinguished from developed countries by the prevalence of calcium-based phosphate binders in prescriptions, and the significant increase in dialysis patients in Asia Pacific, as well as a significant increase in the number of dialysis patients, are expected to boost demand during the period 2023 to 2033.
Due to the increasing aging population, the increasing osteoporosis cases, and changes in dietary habits, the Asia-Pacific market is set to grow at an increasing rate. Hyperphosphatemia drugs are being increasingly used in Asia-Pacific as a consequence of the increasing number of osteoporosis cases and this is the biggest factor driving the market for these drugs.
Iron Based Phosphate Binder Growth will be Fueled by New Clinical Trials
Based on drug class the market is segmented into calcium-based phosphate binders, iron-based phosphate binders, lanthanum carbonate, and non-phosphate binders. According to Future Market Insights, iron-based phosphate binders will continue to dominate the market throughout the forecast period. Approximately 20% of all medical treatments are based on iron-based phosphate binders.
New classes of phosphate binders are based on iron. Clinical trials have been conducted on various iron-based phosphate binders. Two iron-based binders have been approved for clinical use in the United States after being found to be safe and effective in lowering serum phosphate levels: ferric citrate (JTT-751) and sucroferric oxyhydroxide (PA21). In comparison to sucroferric oxyhydroxide, ferric citrate absorbs iron partially.
In order to grow the market for hyperphosphatemia in dialysis patients, growing awareness about phosphorus levels is expected to drive the market. For instance, a new study has found that ferric citrate improved biomarkers of hyperphosphatemia and anemia in patients treated with ferric citrate after clinical trials have granted approval. In comparison with calcium-based binders or sevelamer salts, both of these agents are effective in reducing serum phosphorus levels. A number of factors need to be explored in order to determine their optimal place in therapy, including pill burden, adverse effects on the gastrointestinal system, potential cost reduction strategies for anemia therapies, and the physiological effects of long-term exposure to iron.
The low serum calcium level test is expected to represent 8% of the market at the end of the evaluation period with a CAGR of 3% during the forecast period. As the population ages and calcium levels decrease, the market for low serum calcium level tests is expected to grow as a result of this. Low serum calcium level tests will continue to grow in the market as an increasing number of pregnant women, as well as an increase in bone diseases, is expected to increase market demand for low serum calcium level tests.
A growing number of home-based tests and a growing demand for at-home test kits in the market is expected to lead to a growth in the low serum calcium level test market next year. In addition to this, the growing prevalence of kidney disease and thyroid disease is expected to further contribute to the growth of the market for low serum calcium level tests. As industry advancements continue to grow and more and more customers demand quick test results and more accurate devices, the market is expected to continue growing.
Several domestic and regional players are involved in the hyperphosphatemia market, which is highly fragmented and competitive. Hyperphosphatemia's major market players are investing in Research and Development to learn more about treatment options and determine their accuracy.
The hyperphosphatemia treatment market was valued at US$ 12.1 Billion in 2022
According to Fact.MR, the hyperphosphatemia market is expected to reach US$ 12.66 billion by 2023.
From 2023 to 2033, Fact.MR expects hyperphosphatemia revenue to flourish at a 4.8% CAGR
The hyperphosphatemia market is expected to reach US$ 20.24 Billion by 2033
The North American market is expected to account for more than 36% of industry revenues in 2023.
Europe's hyperphosphatemia market share is expected to increase to 25% by 2033.
Ardelyx, Shield Therapeutics, Sanofi, Takeda Pharmaceutical Company, and Astellas Pharma Inc. are the top 5 market players in the hyperphosphatemia market.
Market share for hyperphosphatemia in Asia Pacific is forecast to reach 32% by 2033.
Hyperphosphatemia in iron-based phosphate binders will account for 20% of the market by 2023.
1. Executive Summary | Hyperphosphatemia Market
1.1. Global Market Outlook
1.2. Demand-side Trends
1.3. Supply-side Trends
1.4. Technology Roadmap Analysis
1.5. Analysis and Recommendations
2. Market Overview
2.1. Market Coverage / Taxonomy
2.2. Market Definition / Scope / Limitations
3. Market Background
3.1. Market Dynamics
3.1.1. Drivers
3.1.2. Restraints
3.1.3. Opportunity
3.1.4. Trends
3.2. Scenario Forecast
3.2.1. Demand in Optimistic Scenario
3.2.2. Demand in Likely Scenario
3.2.3. Demand in Conservative Scenario
3.3. Opportunity Map Analysis
3.4. Investment Feasibility Matrix
3.5. PESTLE and Porter’s Analysis
3.6. Regulatory Landscape
3.6.1. By Key Regions
3.6.2. By Key Countries
3.7. Regional Parent Market Outlook
4. Global Market Analysis 2018 to 2022 and Forecast, 2023 to 2033
4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022
4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033
4.2.1. Y-o-Y Growth Trend Analysis
4.2.2. Absolute $ Opportunity Analysis
5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Drug Class
5.1. Introduction / Key Findings
5.2. Historical Market Size Value (US$ Million) Analysis By Drug Class, 2018 to 2022
5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Drug Class, 2023 to 2033
5.3.1. Calcium-Based Phosphate Binders
5.3.2. Iron-Based Phosphate Binders
5.3.3. Lanthanum Carbonate
5.3.4. Non-Phosphate Binders
5.4. Y-o-Y Growth Trend Analysis By Drug Class, 2018 to 2022
5.5. Absolute $ Opportunity Analysis By Drug Class, 2023 to 2033
6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Test Type
6.1. Introduction / Key Findings
6.2. Historical Market Size Value (US$ Million) Analysis By Test Type, 2018 to 2022
6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Test Type, 2023 to 2033
6.3.1. Low Serum Calcium Level Test
6.3.2. Blood Urea Nitrogen Test
6.3.3. Phosphate Level Test
6.3.4. Creatinine Value Test
6.4. Y-o-Y Growth Trend Analysis By Test Type, 2018 to 2022
6.5. Absolute $ Opportunity Analysis By Test Type, 2023 to 2033
7. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By End User
7.1. Introduction / Key Findings
7.2. Historical Market Size Value (US$ Million) Analysis By End User, 2018 to 2022
7.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By End User, 2023 to 2033
7.3.1. Hospitals
7.3.2. Ambulatory Surgical Centers
7.3.3. Specialty Clinics
7.3.4. Others
7.4. Y-o-Y Growth Trend Analysis By End User, 2018 to 2022
7.5. Absolute $ Opportunity Analysis By End User, 2023 to 2033
8. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region
8.1. Introduction
8.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022
8.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033
8.3.1. North America
8.3.2. Latin America
8.3.3. Western Europe
8.3.4. Eastern Europe
8.3.5. Asia-Pacific
8.3.6. Middle East & Africa (MEA)
8.4. Market Attractiveness Analysis By Region
9. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
9.2.1. By Country
9.2.1.1. The US
9.2.1.2. Canada
9.2.2. By Drug Class
9.2.3. By Test Type
9.2.4. By End User
9.3. Market Attractiveness Analysis
9.3.1. By Country
9.3.2. By Drug Class
9.3.3. By Test Type
9.3.4. By End User
9.4. Key Takeaways
10. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
10.2.1. By Country
10.2.1.1. Brazil
10.2.1.2. Mexico
10.2.1.3. Rest of Latin America
10.2.2. By Drug Class
10.2.3. By Test Type
10.2.4. By End User
10.3. Market Attractiveness Analysis
10.3.1. By Country
10.3.2. By Drug Class
10.3.3. By Test Type
10.3.4. By End User
10.4. Key Takeaways
11. Western Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
11.2.1. By Country
11.2.1.1. Benelux
11.2.1.2. France
11.2.1.3. Germany
11.2.1.4. Italy
11.2.1.5. Nordic
11.2.1.6. Spain
11.2.1.7. The UK
11.2.1.8. Rest of Western Europe
11.2.2. By Drug Class
11.2.3. By Test Type
11.2.4. By End User
11.3. Market Attractiveness Analysis
11.3.1. By Country
11.3.2. By Drug Class
11.3.3. By Test Type
11.3.4. By End User
11.4. Key Takeaways
12. Eastern Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
12.2.1. By Country
12.2.1.1. Poland
12.2.1.2. Russia
12.2.1.3. Rest of Eastern Europe
12.2.2. By Drug Class
12.2.3. By Test Type
12.2.4. By End User
12.3. Market Attractiveness Analysis
12.3.1. By Country
12.3.2. By Drug Class
12.3.3. By Test Type
12.3.4. By End User
12.4. Key Takeaways
13. APAC Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
13.2.1. By Country
13.2.1.1. India
13.2.1.2. Malaysia
13.2.1.3. Singapore
13.2.1.4. Thailand
13.2.1.5. Australia
13.2.1.6. New Zealand
13.2.1.7. Rest of APAC
13.2.2. By Drug Class
13.2.3. By Test Type
13.2.4. By End User
13.3. Market Attractiveness Analysis
13.3.1. By Country
13.3.2. By Drug Class
13.3.3. By Test Type
13.3.4. By End User
13.4. Key Takeaways
14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country
14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022
14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033
14.2.1. By Country
14.2.1.1. GCC Countries
14.2.1.2. South Africa
14.2.1.3. Israel
14.2.1.4. Rest of MEA
14.2.2. By Drug Class
14.2.3. By Test Type
14.2.4. By End User
14.3. Market Attractiveness Analysis
14.3.1. By Country
14.3.2. By Drug Class
14.3.3. By Test Type
14.3.4. By End User
14.4. Key Takeaways
15. Key Countries Market Analysis
15.1. The US
15.1.1. Pricing Analysis
15.1.2. Market Share Analysis, 2022
15.1.2.1. By Drug Class
15.1.2.2. By Test Type
15.1.2.3. By End User
15.2. Canada
15.2.1. Pricing Analysis
15.2.2. Market Share Analysis, 2022
15.2.2.1. By Drug Class
15.2.2.2. By Test Type
15.2.2.3. By End User
15.3. Brazil
15.3.1. Pricing Analysis
15.3.2. Market Share Analysis, 2022
15.3.2.1. By Drug Class
15.3.2.2. By Test Type
15.3.2.3. By End User
15.4. Mexico
15.4.1. Pricing Analysis
15.4.2. Market Share Analysis, 2022
15.4.2.1. By Drug Class
15.4.2.2. By Test Type
15.4.2.3. By End User
15.5. Benelux
15.5.1. Pricing Analysis
15.5.2. Market Share Analysis, 2022
15.5.2.1. By Drug Class
15.5.2.2. By Test Type
15.5.2.3. By End User
15.6. France
15.6.1. Pricing Analysis
15.6.2. Market Share Analysis, 2022
15.6.2.1. By Drug Class
15.6.2.2. By Test Type
15.6.2.3. By End User
15.7. Germany
15.7.1. Pricing Analysis
15.7.2. Market Share Analysis, 2022
15.7.2.1. By Drug Class
15.7.2.2. By Test Type
15.7.2.3. By End User
15.8. Italy
15.8.1. Pricing Analysis
15.8.2. Market Share Analysis, 2022
15.8.2.1. By Drug Class
15.8.2.2. By Test Type
15.8.2.3. By End User
15.9. Nordic
15.9.1. Pricing Analysis
15.9.2. Market Share Analysis, 2022
15.9.2.1. By Drug Class
15.9.2.2. By Test Type
15.9.2.3. By End User
15.10. Spain
15.10.1. Pricing Analysis
15.10.2. Market Share Analysis, 2022
15.10.2.1. By Drug Class
15.10.2.2. By Test Type
15.10.2.3. By End User
15.11. The UK.
15.11.1. Pricing Analysis
15.11.2. Market Share Analysis, 2022
15.11.2.1. By Drug Class
15.11.2.2. By Test Type
15.11.2.3. By End User
15.12. Poland
15.12.1. Pricing Analysis
15.12.2. Market Share Analysis, 2022
15.12.2.1. By Drug Class
15.12.2.2. By Test Type
15.12.2.3. By End User
15.13. Russia
15.13.1. Pricing Analysis
15.13.2. Market Share Analysis, 2022
15.13.2.1. By Drug Class
15.13.2.2. By Test Type
15.13.2.3. By End User
15.14. India
15.14.1. Pricing Analysis
15.14.2. Market Share Analysis, 2022
15.14.2.1. By Drug Class
15.14.2.2. By Test Type
15.14.2.3. By End User
15.15. Malaysia
15.15.1. Pricing Analysis
15.15.2. Market Share Analysis, 2022
15.15.2.1. By Drug Class
15.15.2.2. By Test Type
15.15.2.3. By End User
15.16. Singapore
15.16.1. Pricing Analysis
15.16.2. Market Share Analysis, 2022
15.16.2.1. By Drug Class
15.16.2.2. By Test Type
15.16.2.3. By End User
15.17. Thailand
15.17.1. Pricing Analysis
15.17.2. Market Share Analysis, 2022
15.17.2.1. By Drug Class
15.17.2.2. By Test Type
15.17.2.3. By End User
15.18. Australia
15.18.1. Pricing Analysis
15.18.2. Market Share Analysis, 2022
15.18.2.1. By Drug Class
15.18.2.2. By Test Type
15.18.2.3. By End User
15.19. New Zealand
15.19.1. Pricing Analysis
15.19.2. Market Share Analysis, 2022
15.19.2.1. By Drug Class
15.19.2.2. By Test Type
15.19.2.3. By End User
15.20. GCC Countries
15.20.1. Pricing Analysis
15.20.2. Market Share Analysis, 2022
15.20.2.1. By Drug Class
15.20.2.2. By Test Type
15.20.2.3. By End User
15.21. South Africa
15.21.1. Pricing Analysis
15.21.2. Market Share Analysis, 2022
15.21.2.1. By Drug Class
15.21.2.2. By Test Type
15.21.2.3. By End User
15.22. Israel
15.22.1. Pricing Analysis
15.22.2. Market Share Analysis, 2022
15.22.2.1. By Drug Class
15.22.2.2. By Test Type
15.22.2.3. By End User
16. Market Structure Analysis
16.1. Competition Dashboard
16.2. Competition Benchmarking
16.3. Market Share Analysis of Top Players
16.3.1. By Regional
16.3.2. By Drug Class
16.3.3. By Test Type
16.3.4. By End User
17. Competition Analysis
17.1. Competition Deep Dive
17.1.1. Ardelyx
17.1.1.1. Overview
17.1.1.2. Product Portfolio
17.1.1.3. Profitability by Market Segments
17.1.1.4. Sales Footprint
17.1.1.5. Strategy Overview
17.1.1.5.1. Marketing Strategy
17.1.2. Shield Therapeutics
17.1.2.1. Overview
17.1.2.2. Product Portfolio
17.1.2.3. Profitability by Market Segments
17.1.2.4. Sales Footprint
17.1.2.5. Strategy Overview
17.1.2.5.1. Marketing Strategy
17.1.3. Sanofi
17.1.3.1. Overview
17.1.3.2. Product Portfolio
17.1.3.3. Profitability by Market Segments
17.1.3.4. Sales Footprint
17.1.3.5. Strategy Overview
17.1.3.5.1. Marketing Strategy
17.1.4. Takeda Pharmaceutical Company
17.1.4.1. Overview
17.1.4.2. Product Portfolio
17.1.4.3. Profitability by Market Segments
17.1.4.4. Sales Footprint
17.1.4.5. Strategy Overview
17.1.4.5.1. Marketing Strategy
17.1.5. Astellas Pharma Inc.
17.1.5.1. Overview
17.1.5.2. Product Portfolio
17.1.5.3. Profitability by Market Segments
17.1.5.4. Sales Footprint
17.1.5.5. Strategy Overview
17.1.5.5.1. Marketing Strategy
17.1.6. Akebia Therapeutics Inc.
17.1.6.1. Overview
17.1.6.2. Product Portfolio
17.1.6.3. Profitability by Market Segments
17.1.6.4. Sales Footprint
17.1.6.5. Strategy Overview
17.1.6.5.1. Marketing Strategy
17.1.7. Lupin Ltd.
17.1.7.1. Overview
17.1.7.2. Product Portfolio
17.1.7.3. Profitability by Market Segments
17.1.7.4. Sales Footprint
17.1.7.5. Strategy Overview
17.1.7.5.1. Marketing Strategy
17.1.8. Zeria Pharmaceutical
17.1.8.1. Overview
17.1.8.2. Product Portfolio
17.1.8.3. Profitability by Market Segments
17.1.8.4. Sales Footprint
17.1.8.5. Strategy Overview
17.1.8.5.1. Marketing Strategy
17.1.9. Vifor Pharma Management Ltd.
17.1.9.1. Overview
17.1.9.2. Product Portfolio
17.1.9.3. Profitability by Market Segments
17.1.9.4. Sales Footprint
17.1.9.5. Strategy Overview
17.1.9.5.1. Marketing Strategy
17.1.10. Keryx Biopharmaceuticals
17.1.10.1. Overview
17.1.10.2. Product Portfolio
17.1.10.3. Profitability by Market Segments
17.1.10.4. Sales Footprint
17.1.10.5. Strategy Overview
17.1.10.5.1. Marketing Strategy
18. Assumptions & Acronyms Used
19. Research Methodology
Explore Healthcare Insights
View Reports
Hyperphosphatemia Market
